Edwards Price To Operating Cash Flows Ratio from 2010 to 2024

EW Stock  USD 69.38  0.97  1.38%   
Edwards Lifesciences Price To Operating Cash Flows Ratio yearly trend continues to be fairly stable with very little volatility. Price To Operating Cash Flows Ratio is likely to outpace its year average in 2024. During the period from 2010 to 2024, Edwards Lifesciences Price To Operating Cash Flows Ratio regression line of quarterly data had mean square error of  57.87 and geometric mean of  28.41. View All Fundamentals
 
Price To Operating Cash Flows Ratio  
First Reported
2010-12-31
Previous Quarter
51.64196807
Current Value
54.22
Quarterly Volatility
15.01627363
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Edwards Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edwards Lifesciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 89.7 M, Interest Expense of 10.6 M or Selling General Administrative of 1.8 B, as well as many indicators such as Price To Sales Ratio of 4.36, Dividend Yield of 0.0 or PTB Ratio of 4.82. Edwards financial statements analysis is a perfect complement when working with Edwards Lifesciences Valuation or Volatility modules.
  
Check out the analysis of Edwards Lifesciences Correlation against competitors.

Latest Edwards Lifesciences' Price To Operating Cash Flows Ratio Growth Pattern

Below is the plot of the Price To Operating Cash Flows Ratio of Edwards Lifesciences Corp over the last few years. It is Edwards Lifesciences' Price To Operating Cash Flows Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Edwards Lifesciences' overall financial position and show how it may be relating to other accounts over time.
Price To Operating Cash Flows Ratio10 Years Trend
Slightly volatile
   Price To Operating Cash Flows Ratio   
       Timeline  

Edwards Price To Operating Cash Flows Ratio Regression Statistics

Arithmetic Mean32.72
Geometric Mean28.41
Coefficient Of Variation45.89
Mean Deviation12.13
Median30.96
Standard Deviation15.02
Sample Variance225.49
Range48.7742
R-Value0.87
Mean Square Error57.87
R-Squared0.76
Significance0.000022
Slope2.93
Total Sum of Squares3,157

Edwards Price To Operating Cash Flows Ratio History

2024 54.22
2023 51.64
2022 37.91
2021 46.62
2020 53.87
2019 41.2
2018 34.57

About Edwards Lifesciences Financial Statements

Edwards Lifesciences investors use historical fundamental indicators, such as Edwards Lifesciences' Price To Operating Cash Flows Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Edwards Lifesciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price To Operating Cash Flows Ratio 51.64  54.22 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Edwards Stock Analysis

When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.